← Back to Search

Other

CWP232291 for Acute Myeloid Leukemia

Phase 1 & 2
Waitlist Available
Research Sponsored by JW Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.
Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective in people with relapsed or refractory AML. The primary objective is to assess the efficacy of the drug in combination with another drug, cytarabine.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3rd cycle (each cycle = 28 days), cycle 1 day 1: pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in part a and at cycle 1 day 1: pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in part b. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Recommended Phase 2 dose
Secondary outcome measures
AUC0-t as a Pharmacokinetic (PK) assessments for CWP232291
AUC0-τ as a Pharmacokinetic (PK) assessments for CWP232291
AUC0-∞ as a Pharmacokinetic (PK) assessments for CWP232291
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CWP232291 in combination with cytarabine (ara-C)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CWP232291
2011
Completed Phase 1
~70

Find a Location

Who is running the clinical trial?

JW PharmaceuticalLead Sponsor
67 Previous Clinical Trials
42,547 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
2017. "Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03055286.
All > Acute Myeloid Leukemia > Aml
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top